12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Gattex regulatory update

FDA's Gastrointestinal Drugs Advisory Committee voted 12-0 that Gattex teduglutide from NPS is effective and that the benefits outweigh its risks for treating adults with short bowel syndrome (SBS). The panel concluded that Gattex's reduction in the proportion of patients achieving at least a 20% reduction in...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >